Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers.

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

This study provides valuable insight into the increasing use of obesity drugs. The rising prescription numbers suggest that ...

Prescriptions of obesity management drugs (OMDs) have increased, and these increasing trends are associated with online ...

The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...

The latest attempt focuses on liraglutide, an older, once-daily injectable product in Novo Nordisk's GLP-1 agonist franchise sold as Victoza and Xultophy for diabetes and Saxenda for obesity.

A new study examines how cost, side effects and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

Lexaria Bioscience (LEXX) announced the engagement of a contract research organization to design and execute a human pilot study evaluating DehydraTECH-liraglutide against Saxenda injectable ...

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.